Related by context. Frequent words. (Click for all words.) 65 phase IIa 64 phase IIb 62 axitinib 62 mg kg dose 61 Phase IIa trial 61 Amrubicin 61 Board DSMB 61 events SAEs 60 randomized Phase III 60 tesmilifene 60 placebo controlled clinical 60 double blinded placebo 60 placebo controlled randomized 60 dose cohorts 60 Phase 2b study 60 muraglitazar 60 DSMB 60 glufosfamide 59 Phase III randomized 59 Phase Ia 59 Phase 2a trial 59 Phase IIb clinical 59 Phase 2b clinical 59 Phase IIa clinical 59 Phase 1b trial 59 Phase 2b trial 59 unblinded 59 TELCYTA 58 NSABP 58 Phase 2a clinical 58 tolerated dose MTD 58 multicenter clinical 58 Phase Ib 58 clinical trial 58 sunitinib 58 Mylotarg 58 BAY #-# 58 virologic failure 58 vicriviroc 57 PROMACTA 57 motavizumab 57 dose escalation trial 57 pharmacodynamics 57 relapsed multiple myeloma 57 prospective observational 57 evaluable patients 57 ocrelizumab 57 aflibercept 57 TRITON TIMI 57 valopicitabine 57 candesartan 57 active comparator 57 IIa clinical trial 57 vandetanib 57 nab paclitaxel 56 LIALDA 56 dose escalation 56 Phase 1a 56 Telcyta 56 teduglutide 56 Phenoptin 56 PROPEL trial 56 talabostat 56 registrational 56 SWOG 56 cytogenetic response 56 relapsing remitting multiple sclerosis 56 romiplostim 56 aclidinium 56 darapladib 56 SUTENT 56 GVAX 56 relapsed refractory multiple myeloma 56 Asentar 56 COPAXONE R 56 JAMA. 56 prespecified 56 randomized controlled clinical 56 Phase IIb trial 56 Phase III clinical 56 Phase 1b clinical 56 iclaprim 55 alvimopan 55 tocilizumab 55 REMICADE ® 55 tofacitinib 55 safety tolerability pharmacokinetics 55 abiraterone acetate 55 subgroup analyzes 55 cerebrovascular events 55 HGS ETR1 55 Arch Intern Med 55 IMC A# 55 multicenter randomized 55 Phase 1b 55 placebo controlled trials 55 refractory multiple myeloma 55 lupus nephritis 55 secondary efficacy endpoints 55 label multicenter 55 Diamyd ®